https://www.selleckchem.com/pr....oducts/necrostatin-1
The in-filed ORR was both 100% in all patients and those receiving MTD. The 1-year loco-regional recurrence-free survival rate was 83.3%, 83.3% and 66.7% in dose level 1, 2, and 3, respectively. The MTD of twice-weekly docetaxel and nedaplatin regimen was 5mg/m in inoperable ESCC patients treated with definitive CCRT. Low dose concurrent docetaxel and nedaplatin showed promising radiosensitizing effect on in-filed disease control and good tolerability. The MTD of twice-weekly docetaxel and nedaplatin regimen was 5 mg/m2 in inopera
Like
Comment
Share
